NEW YORK – Ginkgo Bioworks said Monday that it has completed a 1-for-40 reverse stock split following a shareholder vote last week.
The reverse stock split, which will reduce the number of the company's outstanding common shares to about 51.4 million from approximately 2.05 billion, took effect at the beginning of trading on Tuesday.
Shares of Ginkgo were down 6 percent at $8.78 in morning trading on the New York Stock Exchange.
In May, Ginkgo received a continued listing notice from the NYSE after its common stock fell below $1.00 per share for 30 consecutive trading days. The reverse stock split brings the company's share value back above the minimum bid price.
Earlier this month, the Boston-based synthetic biology and biosecurity firm reported a 30 percent year-over-year decline in second quarter revenues after announcing plans to lay off 35 percent of its workforce in June.